THALES
7.1.2020 14:42:11 CET | Business Wire | Press release
Thales has signed a contract to partner with Queensland’s Department of Transport and Main Roads (TMR) in Australia and local Queensland SMEs, Code Heroes and Aliva, to design, develop and deliver the State’s first Digital Licence App.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005628/en/
Thales worked closely with TMR and their customers to co-design a fully integrated app-based solution that is able to manage multiple digital credentials from various sources. The comprehensive solution that integrates a backend platform with managed services, builds upon Gemalto’s next generation Digital ID Platform and Wallet technology, a globally proven and secure, smartphone-based home for all of the owner's digital identity credentials.
Thales completed the acquisition of Gemalto in April 2019 during the TMR procurement process, acquiring a set of highly complementary technologies and competencies, and reinforcing Thales’s status as a world-leader in digital identity and security.
The all-in-one Digital Licence solution utilises a privacy enhanced app that acts as a secure digital vault to store a wide range of digitalized official documents, starting with the owner’s Driver’s Licence, Photo Identification Card, Marine Licence and vehicle registration. The innovative solution delivers ease of access via a smartphone, while ensuring the owner has complete control over their personal data and the freedom to decide exactly what information to share, with whom, and when.
The app will also provide Queenslanders with a secure gateway to access TMR’s online services, supporting the opportunity to expand to other State Government online services in the future.
The innovative solution will be piloted in the Fraser Coast in early 2020, before extending to other regional locations and becoming available to over 3.7 million Queenslanders state-wide.
A first for Australia, Queensland’s Digital Licence will meet the International ISO-Compliant Mobile Driving Licence Standard, allowing the State’s digital driver’s licences to be recognised and used in over 18 countries world-wide including the US, UK and France.
Thales Australia CEO, Chris Jenkins said
“We are excited to be partnering with the Queensland Government to deliver our secure Digital ID Wallet solution. This is the first major contract award in Australia that has resulted from the merger of Thales and Gemalto. The bringing together of two technology powerhouses has strengthened Thales’s position as a world leader in digital security. The Queensland Digital Licence end-to-end solution contract is a demonstration of the success of the integration.”
Note to Editors
Gemalto's solutions are at the heart of modern life, from payments to enterprise security and the internet of things. They authenticate people, transactions and objects, encrypt data and create value for software - enabling companies and governments to deliver secure digital services for billions of individuals and things.
About Thales
The people who make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary, high-technology solutions. Solutions that make tomorrow possible today. From the bottom of the oceans to the depths of space and cyberspace, we help our customers think smarter and act faster – mastering ever greater complexity at every decisive moment along the way.
Thales generated revenues of €19 billion in 2018 with 80 thousand employees in 68 countries.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005628/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom